Literature DB >> 18691602

Chromatin, cancer and drug therapies.

Connie C Cortez1, Peter A Jones.   

Abstract

The structure and organization of chromatin have attracted a great deal of attention recently because of their implications for the field of epigenetics. DNA methylation and the post-translational modifications that occur on histones can specify transcriptional competency. During cancer development, tumor suppressor genes become silenced by DNA hypermethylation and chromatin modifiers no longer perform in their usual manner. Current epigenetic therapy has been able to take advantage of the reversibility of these epimutations. Progress has been made in the treatment of hematological malignancies and some solid tumors. As the knowledge of how chromatin regulates gene expression is enhanced, improvements in the treatment of cancer can be made.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691602      PMCID: PMC2631123          DOI: 10.1016/j.mrfmmm.2008.07.006

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  122 in total

1.  Histone acetylation and globin gene switching.

Authors:  T R Hebbes; A W Thorne; A L Clayton; C Crane-Robinson
Journal:  Nucleic Acids Res       Date:  1992-03-11       Impact factor: 16.971

2.  Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo.

Authors:  P K Chiang; G L Cantoni
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

Review 3.  Decoding the nucleosome.

Authors:  B M Turner
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

Review 4.  Repression and activation by multiprotein complexes that alter chromatin structure.

Authors:  R E Kingston; C A Bunker; A N Imbalzano
Journal:  Genes Dev       Date:  1996-04-15       Impact factor: 11.361

Review 5.  5-Methylcytosine in eukaryotic DNA.

Authors:  M Ehrlich; R Y Wang
Journal:  Science       Date:  1981-06-19       Impact factor: 47.728

6.  Influence of S-adenosylhomocysteine hydrolase inhibitors on S-adenosylhomocysteine and S-adenosylmethionine pool levels in L929 cells.

Authors:  M Cools; E De Clercq
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

7.  Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.

Authors:  J Huggins; Z X Zhang; M Bray
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

Review 8.  DNA methylation in early development.

Authors:  A Razin; R Shemer
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

9.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

10.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.

Authors:  E E Cameron; K E Bachman; S Myöhänen; J G Herman; S B Baylin
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

View more
  23 in total

1.  Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.

Authors:  Xue-Xi Yang; Jing-Zhe Sun; Fen-Xia Li; Ying-Song Wu; Hong-Yan Du; Wei Zhu; Xiang-Hong Li; Ming Li
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 2.  Long antisense non-coding RNAs and their role in transcription and oncogenesis.

Authors:  Kevin V Morris; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

Review 3.  Protein methyltransferases as a target class for drug discovery.

Authors:  Robert A Copeland; Michael E Solomon; Victoria M Richon
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 4.  Common stemness regulators of embryonic and cancer stem cells.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Natalia Papadopoulou; Panagiota Arampatzi; Joseph Papamatheakis; Androniki Kretsovali
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

5.  Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.

Authors:  Jharna Datta; Mozaffarul Islam; Samidha Dutta; Sounak Roy; Quintin Pan; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2016-03-19       Impact factor: 5.337

Review 6.  Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.

Authors:  Diana Markozashvili; Vincent Ribrag; Yegor S Vassetzky
Journal:  Invest New Drugs       Date:  2015-09-30       Impact factor: 3.850

7.  Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells.

Authors:  Éilis Dockry; Seónadh O'Leary; Laura E Gleeson; Judith Lyons; Joseph Keane; Steven G Gray; Derek G Doherty
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

Review 8.  Epigenetics in cancer.

Authors:  Shikhar Sharma; Theresa K Kelly; Peter A Jones
Journal:  Carcinogenesis       Date:  2009-09-13       Impact factor: 4.944

9.  Identifying differentially methylated genes using mixed effect and generalized least square models.

Authors:  Shuying Sun; Pearlly S Yan; Tim H M Huang; Shili Lin
Journal:  BMC Bioinformatics       Date:  2009-12-09       Impact factor: 3.169

10.  A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics.

Authors:  Amy M Quinn; Mark T Bedford; Alexsandra Espejo; Astrid Spannhoff; Christopher P Austin; Udo Oppermann; Anton Simeonov
Journal:  Nucleic Acids Res       Date:  2009-11-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.